Amgen (AMGN) Goodwill & Intangibles (2009 - 2026)
Amgen (AMGN) posted Goodwill & Intangibles of $39.2 billion for Q2 2026, down 2.24% on a QoQ basis from $40.1 billion in Q1 2026, and down 9.55% year-over-year from $43.3 billion in Q2 2025.
Analysis
Amgen (AMGN) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Amgen has reported Goodwill & Intangibles for 18 years, with the latest figure at $39.2 billion in Q2 2026.
- On a quarterly basis, Goodwill & Intangibles fell 9.55% year-over-year to $39.2 billion in Q2 2026; TTM through Jun 2026 was $39.2 billion, a 9.55% decrease from a year earlier, with the FY2025 full-year figure at $41.0 billion, down 11.61% from the prior year.
- Goodwill & Intangibles was $39.2 billion for Q2 2026 at Amgen, down from $40.1 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $51.3 billion in Q4 2023, with the low at $28.1 billion in Q3 2022.
- Average Goodwill & Intangibles over 5 years is $39.0 billion, with a median of $40.5 billion recorded in 2025.
- The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles surged 66.01% in 2024, then retreated 12.11% in 2025.
- Over 5 years, Goodwill & Intangibles stood at $31.6 billion in 2022, then jumped by 62.2% to $51.3 billion in 2023, then decreased by 9.62% to $46.3 billion in 2024, then decreased by 11.61% to $41.0 billion in 2025, then slipped by 4.4% to $39.2 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $39.2 billion (Q2 2026), $40.1 billion (Q1 2026), and $41.0 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.16 Bn |
| Mar 31, 2026 | 40.05 Bn |
| Dec 31, 2025 | 40.96 Bn |
| Sep 30, 2025 | 41.82 Bn |
| Jun 30, 2025 | 43.29 Bn |
| Mar 31, 2025 | 44.37 Bn |
| Dec 31, 2024 | 46.34 Bn |
| Sep 30, 2024 | 47.58 Bn |
| Jun 30, 2024 | 48.79 Bn |
| Mar 31, 2024 | 49.94 Bn |
| Dec 31, 2023 | 51.27 Bn |
| Sep 30, 2023 | 28.66 Bn |
| Jun 30, 2023 | 30.16 Bn |
| Mar 31, 2023 | 30.92 Bn |
| Dec 31, 2022 | 31.61 Bn |
| Sep 30, 2022 | 28.11 Bn |
| Jun 30, 2022 | 28.79 Bn |
| Mar 31, 2022 | 29.46 Bn |
| Dec 31, 2021 | 30.07 Bn |
| Sep 30, 2021 | 29.32 Bn |